Xilio Therapeutics, Inc. (XLO) - Dilution Analysis

S-3/A filing: The company is registering up to $250,000,000 in aggregate securities, including an at-the-market offering of common stock through Leerink Partners for up to $14,500,000.

S-3 filing: Xilio Therapeutics, Inc. filed an S-3 registration statement for an at-the-market offering of common stock with an aggregate offering price of $17,220,000, as part of a broader $250,000,000 shelf registration.

10-Q filing | 5.8M shares outstanding

10-K filing | 5.8M shares outstanding

10-Q filing | 52.5M shares outstanding

10-Q filing | 51.8M shares outstanding

10-Q filing | 51.8M shares outstanding

S-3/A filing: Xilio Therapeutics, Inc. may offer and sell securities from time to time in one or more offerings of up to $250,000,000 in aggregate offering price. The net proceeds from this offering will be used for working capital, capital expenditures and other general corporate purposes.

10-K filing | 53.5M shares outstanding

S-3 filing: Xilio Therapeutics, Inc. may offer and sell securities from time to time in one or more offerings of up to $250,000,000 in aggregate offering price.

8-K filing: Xilio Therapeutics, Inc. entered into a collaboration, license and option agreement with AbbVie Group Holdings Limited, including an equity investment by AbbVie in Xilio's common stock. The Company sold 4,347,826 shares of its common stock to AbbVie Inc. at a purchase price of $2.30 per share for an aggregate purchase price of $10.0 million. ($10.0M proceeds)

8-K filing: Xilio Therapeutics, Inc. completed the sale of an aggregate of 1,759,978 shares of common stock and a prefunded warrant to purchase up to an aggregate of 6,092,816 shares of common stock to Gilead Sciences, Inc. on December 18, 2024, for approximately $8.2 million in gross proceeds, completing the $25.0 million aggregate investment under the Stock Purchase Agreement. ($0.0M proceeds)

10-Q filing | 44.0M shares outstanding

10-Q filing | 44.0M shares outstanding

10-Q filing | 36.9M shares outstanding

S-3 filing: This S-3 filing relates to the resale of up to 17,580,566 shares of common stock of Xilio Therapeutics by selling stockholders, including shares issuable upon the exercise of outstanding pre-funded warrants.

10-K filing | 34.5M shares outstanding

8-K filing: Xilio Therapeutics entered into a license agreement with Gilead, including an initial equity investment by Gilead, and also entered into a securities purchase agreement with accredited investors for a private placement. ($24.8M proceeds)

8-K filing: Xilio Therapeutics, Inc. closed a private placement with Gilead Sciences, Inc. on March 28, 2024, issuing 6,860,223 shares of common stock at $1.97 per share for approximately $13.5 million. ($13.5M proceeds)

10-Q filing | 27.5M shares outstanding

10-Q filing | 27.5M shares outstanding

10-Q filing | 27.4M shares outstanding

10-K filing | 27.4M shares outstanding

10-Q filing | 27.4M shares outstanding

S-3 filing: Xilio Therapeutics, Inc. may offer and sell common stock, preferred stock, debt securities, units, and warrants from time to time in one or more offerings up to $250,000,000 in aggregate offering price.

10-Q filing | 27.4M shares outstanding

10-Q filing | 27.4M shares outstanding

10-K filing | 27.5M shares outstanding

10-Q filing | 27.5M shares outstanding

S-1/A filing: This S-1/A filing outlines an offering of common stock with an option to purchase additional shares, intended for advancing clinical trials and general corporate purposes.